CD49d expression as a promising biomarker to monitor natalizumab efficacy

Journal of the Neurological Sciences

Volumn 314, Issue 1-2, 2012, Pages 138-142

  Defer, Gilles ^a,b,c   Mariotte, Delphine ^a   Derache, Nathalie ^a   Toutirais, Olivier ^a,b,c   Legros, Hélène ^a   Cauquelin, Brigitte ^a   Le Mauff, Brigitte ^a,b,c  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c INSERM   (France)

Author keywords

CD49d VLA 4; Multiple sclerosis; Natalizumab; Neutralizing antibodies

Indexed keywords

ALPHA4 INTEGRIN; NATALIZUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENERAL ASPECTS OF DISEASE; HAND EDEMA; HUMAN; HYPERSENSITIVITY; MALE; MULTIPLE SCLEROSIS; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SKIN ALLERGY; TACHYCARDIA; TREATMENT DURATION; URTICARIA; VERTIGO;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; BIOLOGICAL MARKERS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INTEGRIN ALPHA4; KINETICS; LYMPHOCYTES; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MONOCYTES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; TREATMENT FAILURE; YOUNG ADULT;

EID: 84857043047     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.10.005     Document Type: Article

References (19)

1. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 9 2006 899 910
2. R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, and E.W. Radue Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 9 2006 911 923
3. B. Cannella, and C.S. Raine The adhesion molecule and cytokine profile of multiple sclerosis lesions Ann Neurol 37 4 1995 424 435
4. M. Niino, C. Bodner, M.L. Simard, S. Alatab, D. Gano, and H.J. Kim Natalizumab effects on immune cell responses in multiple sclerosis Ann Neurol 59 5 2006 748 754
5. T.A. Yednock, C. Cannon, L.C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356 6364 1992 63 66
6. S.J. Kent, S.J. Karlik, G.P. Rice, and H.C. Horner A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig J Magn Reson Imaging 5 5 1995 535 540
7. E.W. Radue, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, and R.A. Rudick Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis J Neurol Sci 292 1-2 2010 28 35
8. B.A. Cohen, J. Oger, A. Gagnon, and G. Giovannoni The implications of immunogenicity for protein-based multiple sclerosis therapies J Neurol Sci 275 1-2 2008 7 17
9. P.A. Calabresi, G. Giovannoni, C. Confavreux, S.L. Galetta, E. Havrdova, and M. Hutchinson The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL Neurology 69 14 2007 1391 1403
10. M. Cohen, F. Rocher, S. Vivinus, P. Thomas, and C. Lebrun Giant urticaria and persistent neutralizing antibodies after the first natalizumab infusion Neurology 74 17 2010 1394 1395
11. K. Hellwig, S. Schimrigk, M. Fischer, A. Haghikia, T. Muller, and A. Chan Allergic and nonallergic delayed infusion reactions during natalizumab therapy Arch Neurol 65 5 2008 656 658
12. F. Sangalli, L. Moiola, S. Bucello, P. Annovazzi, A. Rizzo, and M. Radaelli Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study Neurol Sci 31 S3 2010 299 302
13. B. Oliver, O. Fernandez, T. Orpez, M.P. Alvarenga, M.J. Pinto-Medel, and M. Guerrero Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months Mult Scler 17 3 2011 368 371
14. P. Wipfler, K. Oppermann, G. Pilz, S. Afazel, E. Haschke-Becher, and A. Harrer Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment Mult Scler 17 1 2011 16 23
15. R. Gold, A. Jawad, D.H. Miller, D.C. Henderson, A. Fassas, and W. Fierz Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies J Neuroimmunol 187 1-2 2007 156 158
16. M. Soilu-Hanninen, M. Laaksonen, A. Hanninen, J.P. Eralinna, and M. Panelius Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS J Neuroimmunol 167 1-2 2005 175 182
17. P.K. Coyle, J.F. Foley, E.J. Fox, D.R. Jeffery, F.E. Munschauer, and C. Tornatore Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy Mult Scler 15 S4 2009 S26 S36
18. E.J. Fox, T.K. Vartanian, and S.S. Zamvil The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists Neurologist 13 6 2007 355 362
19. G.S. Francis, G.P. Rice, and J.C. Alsop Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS Neurology 65 1 2005 48 55